Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma

Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembo...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2019-04, Vol.19 (1), p.363-363, Article 363
Main Authors: Park, Yehyun, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Yeon, Jong Eun, Byun, Kwan Soo, Kim, Hye Soo, Kim, Ji Hoon, Kim, Seung Up
Format: Article
Language:English
Subjects:
Albumin
Analysis
Bilirubin
Cancer
Cancer research
Cancer therapies
Cancer treatment
Carcinoma
Care and treatment
Disease
Embolization
Glycoproteins
Health risk assessment
Hepatocellular carcinoma
Hepatology
Hepatoma
Hepatoma arterial-embolization prognostic score
Hospitals
Liver cancer
Medical prognosis
Medical schools
Patients
Prognosis
Risk assessment
Risk prediction
Sorafenib
Survival
Systematic review
Therapeutic chemoembolization
Trans-arterial chemoembolization
Tumors
α-Fetoprotein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE. A total of 619 HCC patients treated with TACE from two institutions between 2003 and 2010 were included. Patients with A-B class risk scores showed significantly better survival than those with C-D class risk scores at the first (median 43.7 vs. 21.5 months for mHAP-II, 35.2 vs. 10.2 months for mHAP, and 39.8 vs. 18.6 months for HAP; all P 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-019-5495-6